Jeffrey E. Lancet

Hematology

12902 Usf Magnolia Dr
Tampa, FL 33612

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 205 publications

Correction: CPX-351 vs. conventional chemotherapy cardiotoxicity in high-risk AML: a post hoc phase III trial analysis.

Correction: CPX-351 vs. conventional chemotherapy cardiotoxicity in high-risk AML: a post hoc phase III trial analysis.

Journal: Cardio-oncology (London, England)

Published: May 23, 2026

Cardiovascular Adverse Events During Venetoclax-Based Treatment in Acute Myeloid Leukemia.

Cardiovascular Adverse Events During Venetoclax-Based Treatment in Acute Myeloid Leukemia.

Journal: Journal of the American Heart Association

Published: May 06, 2026

Impact of race on mutational profile and survival in acute myeloid leukemia: a single-institution experience (2014-2024).

Impact of race on mutational profile and survival in acute myeloid leukemia: a single-institution experience (2014-2024).

Journal: Annals of hematology

Published: April 02, 2026

Clinical and Genomic Convergence of High-Risk CCUS and Lower-Risk Myelodysplastic Syndromes/Neoplasms.

Clinical and Genomic Convergence of High-Risk CCUS and Lower-Risk Myelodysplastic Syndromes/Neoplasms.

Journal: Blood

Published: January 08, 2026

CPX-351 selectively benefits patients with AML and myelodysplasia-related mutations in the pivotal randomized trial.

CPX-351 selectively benefits patients with AML and myelodysplasia-related mutations in the pivotal randomized trial.

Journal: Blood advances

Published: December 11, 2025

CPX-351 Selectively Benefits Patients with AML and Myelodysplasia-Related Mutations in the Pivotal Randomized Trial.

CPX-351 Selectively Benefits Patients with AML and Myelodysplasia-Related Mutations in the Pivotal Randomized Trial.

Journal: Blood advances

Published: December 11, 2025

Baseline IPSS-M vs Pretransplant Risk Downstaging as Prognostic Determinants in MDS Undergoing Allogeneic Transplantation.

Baseline IPSS-M vs Pretransplant Risk Downstaging as Prognostic Determinants in MDS Undergoing Allogeneic Transplantation.

Journal: Blood advances

Published: September 16, 2025

Baseline IPSS-M vs pretransplant risk downstaging as prognostic determinants in MDS undergoing allogeneic transplantation.

Baseline IPSS-M vs pretransplant risk downstaging as prognostic determinants in MDS undergoing allogeneic transplantation.

Journal: Blood advances

Published: September 16, 2025

CMML is in the eye of the be-WHO-lder: interrogating the newly proposed entity of oligomonocytic CMML: MDS or CMML?

CMML is in the eye of the be-WHO-lder: interrogating the newly proposed entity of oligomonocytic CMML: MDS or CMML?

Journal: Blood neoplasia

Published: September 08, 2025

Real-world prevalence and outcome of elevated right ventricular systolic pressure in myelofibrosis.

Real-world prevalence and outcome of elevated right ventricular systolic pressure in myelofibrosis.

Journal: Cardio-oncology (London, England)

Published: August 23, 2025

American Society of Hematology 2025 guidelines for treating newly diagnosed acute myeloid leukemia in older adults.

American Society of Hematology 2025 guidelines for treating newly diagnosed acute myeloid leukemia in older adults.

Journal: Blood advances

Published: July 30, 2025

American Society of Hematology 2025 guidelines for treating newly diagnosed acute myeloid leukemia in older adults.

American Society of Hematology 2025 guidelines for treating newly diagnosed acute myeloid leukemia in older adults.

Journal: Blood advances

Published: July 30, 2025

Showing 1-12 of 205

Last Updated: 09/26/2026